First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.

Phase 3 Recruiting 124 enrolled Gustave Roussy, Cancer Campus, Grand Paris

RandomizedParallel-groupOpen-labelTreatment

Summary

First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study

Timeline

Start: 2025-09-09
Primary completion: 2030-02
Completion: 2030-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Atezolizumab	Monoclonal antibody	—	—
Background	Cemiplimab	Monoclonal antibody	—	—
Background	Durvalumab	Monoclonal antibody	—	—
Background	Ipilimumab	Monoclonal antibody	—	—
Background	Nivolumab	Monoclonal antibody	—	—
Background	Paclitaxel	Small molecule	—	—
Background	Pembrolizumab	Monoclonal antibody	—	—
Background	Pemetrexed	Small molecule	—	—
Background	Tremelimumab	Monoclonal antibody	—	—

First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.

Summary

Timeline

Drugs

Indications